Qualia Life Sciences
This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.
Objectives Within-group changes in outcomes will be compared from baseline to the end of the study period. Primary Outcome Measures: Biomarkers in blood, measured using the Olink Target 48 Cytokine panel: Tumor Necrosis Factor (TNF) Interleukin-1 Beta (IL1B) Interleukin-8 (CXCL8) Vascular Endothelial Growth Factor A (VEGFA) Secondary Outcome Measures: Remaining biomarkers in the Olink Target 48 Cytokine panel 36-Item Short Form Health Survey (SF-36) Frailty Index for Elders (FIFE) Depression Anxiety Stress Scale-21 (DASS-21) Side effect profile including: Number, type, severity, causali…
Inclusion Criteria: * Provide voluntary, written, informed consent to participate in the study * Agree to provide a valid cell phone number and are willing to receive communications through text. * Healthy adults 45 - 79 years of age Can read and write English * Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly. * Willing to self-administer the fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives NHC access to the results of these test…
Qualia Senolytic manufactured by Qualia Life Science
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.